BioSpace News Archive

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that new research on its investigational drug EVO100 for the prevention of chlamydia and gonorrhea in women will be highlighted in a poster presentation at the annual meeting of the Professional Society for Health Economics and Outcomes Research, Virtual ISPOR 2021

Transaction Data Systems (“TDS”), a leader in pharmacy software solutions and services, today announced that BlackRock Long Term Private Capital (“LTPC”) has acquired a majority interest in the company. TDS’ previous owner, GTCR, will retain a minority interest.

Collaboration supports co-development of RB-340, a HER-2 targeted CAR T- cell therapy with context-dependent and inducible down-regulation of PD-1, through Phase 2 MD Anderson to apply Refuge’s synthetic biology platform to TIL programs

bHAVN Life Sciences Inc., a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it has entered into a definitive agreement to acquire clinical stage intellectual property from Bolt Therapeutics.

Halberd Corporation (OTC PINK:HALB) announces the successful conjugation of gold-coated iron nanoparticles with Halberds patent-pending monoclonal antibody against the SARS-CoV-2 spike protein. This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy to bodily fluids of infected patients.

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina specialist, effective today.

First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials business updates

Accomplished leader involved in helping secure FDA approvals for over 100 new medicines joins n-Lorem Foundation to aid in its mission to provide individualized therapies to the ultra-rare disease community

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT.

Illumina, Inc. (NASDAQ: ILMN) today announced that it is appointing Susan Tousi as Chief Commercial Officer (CCO), and Dr. Alex Aravanis as Chief Technology Officer (CTO), Head of Research and Product Development.